Article
Hematology
Colleen A. Ramsower, Allison Rosenthal, Ryan S. Robetorye, Raphael Mwangi, Matthew Maurer, Diego Villa, Tim McDonnell, Andrew Feldman, Jonathon B. Cohen, Thomas Habermann, Elias Campo, Guillem Clot, Marco M. Buhler, Marta Kulis, Jose Ignacio Martin-Subero, Eva Gine, James R. Cook, Brian Hill, Philipp W. Raess, Klaus H. Beiske, Alexander Reichart, Sylvia Hartmann, Harald Holte, David Scott, Lisa Rimsza
Summary: In this study, a comprehensive comparison of clinicopathological features in older mantle cell lymphoma (MCL) patients was undertaken. The strongest prognostic indicators were identified as the simplified MCL international prognostic index (s-MIPI) and MCL35, along with blastoid cytology. Combining MIPI with MCL35 to assess proliferation may be an effective method for risk stratification in older MCL patients in future clinical trials.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Genetics & Heredity
Xin Zhang, Yang Han, Yu Nie, Yujie Jiang, Xiaohui Sui, Xueling Ge, Fang Liu, Ya Zhang, Xin Wang
Summary: This study reveals the prognostic value of PAX5 in mantle cell lymphoma and establishes a new risk scoring system, MIPI-SP, which outperforms the MIPI score in predicting prognosis.
JOURNAL OF MOLECULAR MEDICINE-JMM
(2023)
Article
Hematology
Yue-Hua Zhang, Li-Min Gao, Xiao-Yu Xiang, Wen-Yan Zhang, Wei-Ping Liu
Summary: This study aimed to investigate the optimal cut-off value for p53 in predicting prognosis of MCL patients and the feasibility of using computer image analysis to determine the positive rate of p53. The results showed that setting the cut-off value of p53 at 20% can effectively predict the prognosis of MCL patients. Additionally, computer image analysis can replace semiquantitative estimation and has better prospects in MCL.
ANNALS OF HEMATOLOGY
(2022)
Article
Oncology
Tao Wang, Wenqin Yue, Gusheng Tang, Mingyu Ye, Jiechen Yu, Bin Liu, Lijuan Jiao, Xuefei Liu, Shuyi Yin, Jie Chen, Lei Gao, Jianmin Yang, Miaoxia He
Summary: SAMHD1 is a protein that regulates innate immunity and DNA damage signaling, with high expression positively correlated with lower chemotherapy response rate and shorter overall survival in mantle cell lymphoma (MCL) patients, serving as an adverse biomarker. Silencing the SAMHD1 gene in MCL cell lines reduces cell proliferation and increases apoptosis, as well as enhances sensitivity to cytarabine. Four previously unreported missense mutations in the SAMHD1 gene were detected, although their biological functions remain to be elucidated.
FRONTIERS IN ONCOLOGY
(2021)
Review
Oncology
Yu Zhou, Haizhu Chen, Yunxia Tao, Qiaofeng Zhong, Yuankai Shi
Summary: This meta-analysis found that MRD positivity was associated with worse survival outcomes in mantle cell lymphoma, suggesting the important prognostic value of MRD in MCL patients and the need for further research.
Review
Biochemistry & Molecular Biology
Leigh Deshotels, Firas M. M. Safa, Nakhle S. S. Saba
Summary: Although major progress has been made in mantle cell lymphoma (MCL) therapeutics, MCL still has a poor prognosis with a median survival of less than four years. Several genes, including NOTCH1 and NOTCH2, have been found to be mutated in MCL, leading to upregulation of genes involved in angiogenesis, cell cycle progression, and cell migration and adhesion. Mutated NOTCH genes are associated with aggressive features in MCL and inferior survival. This article discusses the role of NOTCH signaling in MCL biology and ongoing efforts for targeted therapeutic interventions.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Hematology
Jin-Hua Liang, Yi-Min Ren, Kai-Xin Du, Rui Gao, Zi-Wen Duan, Jing-Ran Guo, Tong-Yao Xing, Wei-Ting Wang, Li Wang, Yan Wang, Rong Wang, Jian-Yong Li, Wei Xu
Summary: Reprogramming of nucleotide metabolism is crucial in mantle cell lymphoma and is associated with different transcriptional signaling pathways and prognosis. A prognostic model incorporating six genes, including CTPS1, accurately predicts the prognosis of MCL patients. Increased expression of CTPS1 is an independent prognostic factor for adverse overall survival and progression-free survival.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Cell Biology
Esra Esmeray Sonmez, Tevfik Hatipoglu, Deniz Kursun, Xiaozhou Hu, Burcu Akman, Hongling Yuan, Ayca Ersen Danyeli, Inci Alacacioglu, Sermin Ozkal, Aybuke Olgun, Taner Kemal Erdag, Hua You, Can Kucuk
Summary: This study identified genes and transcripts associated with the development and prognosis of mantle cell lymphoma (MCL) through transcriptome sequencing. The high expression of VWF mRNA and low expression of FTX lncRNA were found to be associated with poor overall survival in MCL cases. Additionally, the ratio of tumor-infiltrating immunocytes was also correlated with overall survival in MCL patients.
Article
Cell Biology
Dahai Liu, Fei Qi, Wei Liu, Justin Liu, Jun Wang, Dao-Qiang Lu, Yang Xun, Min-Min Chen, Xin Chen, Shu-Ting Yang, Wen-Qiao Jiao, Zong-Ye Li, Fang Liu, Hua Yang, Wen-Xing Li
Summary: This study explored the expression and function of cytokines in Hodgkin's lymphoma (HL), diffuse large B-cell lymphoma (DLBCL), and mantle cell lymphoma (MCL). The results showed shared immune functions and signal pathway damage in all three types of lymphoma, and these functions were related to cytokines. Furthermore, CXCL14 was identified as a key regulator affecting cell chemotaxis and migration functions.
Article
Biochemistry & Molecular Biology
Jimena Alvarez Freile, Natasha Ustyanovska Avtenyuk, Macarena Gonzalez Corrales, Harm Jan Lourens, Gerwin Huls, Tom van Meerten, Ewa Cendrowicz, Edwin Bremer
Summary: This study investigates the expression and therapeutic effects of CD24 and CD47, two immune checkpoints, in B-cell lymphoma. The results show that CD24 is associated with poor survival in MCL patients, while CD47 is associated with survival in DLBCL patients. CD24 antibody treatment exhibits potent phagocytic effects in MCL, but not in DLBCL.
Review
Oncology
Panruo Jiang, Aakash Desai, Haige Ye
Summary: Mantle cell lymphoma (MCL) is known as one of the most aggressive lymphoid tumors, but some cases may exhibit indolent behavior referred to as smoldering MCL (SMCL). Understanding the molecular mechanisms of indolent MCL, which differ significantly from classical MCL, can help differentiate these two types of lymphoma and guide appropriate treatment strategies.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY
(2021)
Article
Oncology
Husain Yar Khan, Md. Hafiz Uddin, Suresh Kumar Balasubramanian, Noor Sulaiman, Marium Iqbal, Mahmoud Chaker, Amro Aboukameel, Yiwei Li, William Senapedis, Erkan Baloglu, Ramzi M. Mohammad, Jeffrey Zonder, Asfar S. Azmi
Summary: Targeting PAK4 and NAMPT using the small molecule inhibitor KPT-9274 can inhibit cell proliferation, deplete energy, and induce apoptosis in various NHL subtypes. KPT-9274 treatment shows potent anti-tumor effects in experimental models, suggesting its potential as a novel therapy for NHL.
Review
Oncology
Xue Wu, Hongyu Lu, Tao Pang, Xue Li, Hongzhi Luo, Hong Tan, Shan Liu
Summary: Studies have shown that MRD negativity in MCL patients is associated with improved overall survival and progression-free survival compared to MRD positivity. Consistent results were found across different subgroups based on sample sources and MRD detection time points.
Review
Biochemistry & Molecular Biology
Zoufang Huang, Vivek P. Chavda, Rajashri Bezbaruah, Hemant Dhamne, Dong-Hua Yang, Hong-Bing Zhao
Summary: Mantle cell lymphoma (MCL) is a subtype of Non-Hodgkin lymphoma characterized by translocation of Cyclin D1. Despite progress in understanding the causes and available treatments, MCL remains incurable. CAR-T cell therapy shows potential for treating B-cell malignancies and MCL.
Article
Hematology
Huan-Ping Wang, Yi-Le Zhou, Xin Huang, Yi Zhang, Jie-Jing Qian, Jian-Hu Li, Xue-Ying Li, Chen-Ying Li, Yin-Jun Lou, Wen-Yuan Mai, Hai-Tao Meng, Wen-Juan Yu, Hong-Yan Tong, Jie Jin, Hong-Hu Zhu
Summary: The study investigated the characteristics and prognostic value of CDKN2A gene deletions in T-ALL patients, finding an association with younger age, higher white blood cell count, and higher lactate dehydrogenase levels. Patients with CDKN2A deletion had lower survival rates and it was identified as an independent adverse prognostic factor for overall survival. These patients may benefit from intensive chemotherapy or stem-cell transplantation.
AMERICAN JOURNAL OF HEMATOLOGY
(2021)